TCID, Ubiquitin C-terminal Hydrolase-L3 (UCH-L3) Inhibitor

TCID is a novel potent and selective inhibitor of ubiquitin C-terminal hydrolase-L3 (UCH-L3) with an IC50 ~0.6 μM. It has ~125-fold greater selectivity over UCH-L1 (ubiquitin C-terminal hydrolase L1, IC50 ~75 μM). TCID can diminish glycine transporter GlyT2 ubiquitination in brain stem and spinal cord primary neurons.

Product information

CAS Number: 30675-13-9

Molecular Weight: 283.92

Formula: C9H2Cl4O2

Chemical Name: 4,5,6,7-Tetrachloro-1H-Indene-1,3(2H)-dione

Smiles: O=C1CC(=O)C2=C1C(Cl)=C(Cl)C(Cl)=C2Cl

InChiKey: IDLAOWFFKWRNHB-UHFFFAOYSA-N

InChi: InChI=1S/C9H2Cl4O2/c10-6-4-2(14)1-3(15)5(4)7(11)9(13)8(6)12/h1H2

Technical Data

Appearance: Solid Power.

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO up to 50 mM

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined.

HS Tariff Code: 382200

How to use

In Vitro:

TCID was used at 10-30 µM final concentration in various in vitro assays.

References:

1. Liu Y, et al. Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. (2003) Chem Biol. 10(9):837-46.
2. e Juan-Sanz J, et al. Constitutive endocytosis and turnover of the neuronal glycine transporter GlyT2 is dependent on ubiquitination of a C-terminal lysine cluster. (2013) PLoS One. 8(3):e58863.

Products are for research use only. Not for human use.